Cue biopharma announces completion of patient enrollment in phase 1b study of cue-101 in combination with keytruda®

Boston, sept. 26, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, today announced that it has completed patient enrollment in its phase 1 clinical trial (nct03978689) evaluating cue-101, the company's lead interleukin 2 (il-2)-based biologic from the cue-100 series, in combination with keytruda® (pembrolizumab) as first-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (hpv+ r/m hnscc).
CUE Ratings Summary
CUE Quant Ranking